LONDON — (BUSINESS WIRE) — Jetcraft, the global leader in business aircraft sales, acquisitions and trades, is releasing Ever Forward, its 5-Year Pre-Owned Business Jet Market Forecast, id…
NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the treatment of patients with BRCA-mutated t…